Dalian Yalifeng Biopharmaceutical Begins Influenza A/H1N1 Vaccine Production
This article was originally published in PharmAsia News
Executive Summary
Dalian Yalifeng Biopharmaceutical has started to produce China's first batch of Influenza A/H1N1 vaccine. Upon receiving the H1N1 virus strain from WHO, the company has begun inoculation of chicken eggs for experiments. The vaccine production procedure will begin with virus amplification, followed by extraction of its surface antigen to produce the antibody. The first batch of six million doses is expected to be produced in Dalian by the end of September. The city's FDA will closely monitor the entire production process to ensure compliance with WHO standards. (Click here for more - Chinese Language)
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.